Free Trial

Evolus (EOLS) Competitors

Evolus logo
$6.40 +0.10 (+1.59%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$6.35 -0.05 (-0.78%)
As of 10/17/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EOLS vs. RCUS, HRMY, AUPH, PAHC, SDGR, HROW, SNDX, EVO, ZYME, and AVDL

Should you be buying Evolus stock or one of its competitors? The main competitors of Evolus include Arcus Biosciences (RCUS), Harmony Biosciences (HRMY), Aurinia Pharmaceuticals (AUPH), Phibro Animal Health (PAHC), Schrodinger (SDGR), Harrow (HROW), Syndax Pharmaceuticals (SNDX), Evotec (EVO), Zymeworks (ZYME), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical products" industry.

Evolus vs. Its Competitors

Evolus (NASDAQ:EOLS) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Evolus has higher revenue and earnings than Arcus Biosciences. Evolus is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evolus$266.27M1.55-$50.42M-$0.98-6.53
Arcus Biosciences$258M6.80-$283M-$3.17-5.20

In the previous week, Arcus Biosciences had 8 more articles in the media than Evolus. MarketBeat recorded 10 mentions for Arcus Biosciences and 2 mentions for Evolus. Evolus' average media sentiment score of 0.43 beat Arcus Biosciences' score of -0.08 indicating that Evolus is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Evolus
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arcus Biosciences
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Neutral

Evolus has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.

Evolus has a net margin of -22.31% compared to Arcus Biosciences' net margin of -109.56%. Arcus Biosciences' return on equity of -55.96% beat Evolus' return on equity.

Company Net Margins Return on Equity Return on Assets
Evolus-22.31% -759.04% -24.63%
Arcus Biosciences -109.56%-55.96%-25.73%

90.7% of Evolus shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 5.9% of Evolus shares are held by insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Evolus presently has a consensus target price of $21.25, suggesting a potential upside of 232.03%. Arcus Biosciences has a consensus target price of $26.78, suggesting a potential upside of 62.39%. Given Evolus' higher possible upside, analysts clearly believe Evolus is more favorable than Arcus Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evolus
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Arcus Biosciences
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60

Summary

Evolus and Arcus Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

Get Evolus News Delivered to You Automatically

Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EOLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EOLS vs. The Competition

MetricEvolusMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$407.52M$10.71B$6.10B$10.50B
Dividend YieldN/A1.88%5.73%4.81%
P/E Ratio-6.5319.6784.5227.09
Price / Sales1.5531.17586.66210.72
Price / CashN/A25.0337.1661.22
Price / Book71.113.4112.246.52
Net Income-$50.42M$210.63M$3.32B$276.75M
7 Day Performance4.23%0.03%1.25%2.00%
1 Month Performance-0.31%-1.38%6.28%2.26%
1 Year Performance-61.49%-9.70%59.92%35.58%

Evolus Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EOLS
Evolus
3.9389 of 5 stars
$6.40
+1.6%
$21.25
+232.0%
-61.5%$407.52M$266.27M-6.53170Analyst Forecast
RCUS
Arcus Biosciences
2.3868 of 5 stars
$16.64
+14.0%
$23.38
+40.5%
-9.6%$1.55B$258M-5.25500Gap Up
HRMY
Harmony Biosciences
4.7598 of 5 stars
$26.36
-0.7%
$46.11
+74.9%
-25.9%$1.53B$714.73M8.50200Analyst Forecast
AUPH
Aurinia Pharmaceuticals
2.8876 of 5 stars
$11.10
-1.5%
$13.00
+17.1%
+60.9%$1.48B$235.13M25.81300
PAHC
Phibro Animal Health
4.0633 of 5 stars
$36.58
+0.5%
$28.40
-22.4%
+63.1%$1.48B$1.30B31.002,475Analyst Forecast
SDGR
Schrodinger
3.4427 of 5 stars
$19.70
+3.2%
$26.29
+33.4%
+9.8%$1.40B$207.54M-7.94790Analyst Forecast
HROW
Harrow
2.9417 of 5 stars
$38.77
+3.4%
$68.50
+76.7%
-29.1%$1.39B$199.61M-155.08180
SNDX
Syndax Pharmaceuticals
3.987 of 5 stars
$15.20
-5.4%
$39.22
+158.0%
-28.1%$1.38B$23.68M-3.91110News Coverage
Analyst Upgrade
EVO
Evotec
1.6617 of 5 stars
$3.95
+2.1%
$7.00
+77.2%
+26.0%$1.37B$862.40M0.004,827News Coverage
Gap Down
ZYME
Zymeworks
2.7597 of 5 stars
$18.11
+0.3%
$22.50
+24.2%
+36.6%$1.36B$122.87M-12.07460Trending News
Analyst Forecast
Analyst Revision
AVDL
Avadel Pharmaceuticals
2.5985 of 5 stars
$14.20
+1.4%
$20.86
+46.9%
+9.3%$1.36B$169.12M-473.3370

Related Companies and Tools


This page (NASDAQ:EOLS) was last updated on 10/18/2025 by MarketBeat.com Staff
From Our Partners